Mundipharma and Endoceutics to Exclusively License Intrarosa™ (Prasterone) in MEA Region


Mundipharma and Endoceutics to Exclusively License Intrarosa™ (Prasterone) in MEA Region

PR Newswire

DUBAI, UAE, May 20, 2018 /PRNewswire/ —

A unique non-estrogen prescription therapy, Intrarosa™, has been approved by the US Food and Drug Administration (FDA) and by the European Medical Agency (EMA), for the treatment of the most bothersome symptom of vulvovaginal atrophy, due to menopause, known as dyspareunia. 

Mundipharma has been granted the commercial rights to Intrarosa™ (Prasterone) in the Middle East and Africa as part of an agreement signed between Mundipharma and Endoceutics, Inc. 

     (Logo: )

     (Logo: )

Intrarosa™ (Prasterone) has been developed for the treatment of women experiencing moderate to severe dyspareunia, which is an outcome of vulvovaginal atrophy, that occurs due to menopause. Intrarosa™ is a unique non-estrogen product that is administered locally in order to exert an action limited to the vagina.[1]

Intrarosa™ was approved by the FDA in the US and by EMA for all countries of Europe. As the unique intracellular precursor of sex steroids in women, Intrarosa™ (Prasterone) is transformed into androgens and estrogens inside the vaginal cells without any biologically significant increase in estrogens or androgens found in the patient’s blood. [1]

Ashraf Allam, Vice President of Mundipharma in the Middle East, Turkey and Africa Region, said: “Intrarosa™ is an unique new innovation that successfully tackles an important health issue for postmenopausal women who suffer from the painful condition of dyspareunia.  We are looking forward to make this treatment available to women of our region. We are very excited to work with Professor Fernand Labrie, the founder and CEO of Endoceutics who has been at the forefront of this ground-breaking innovation”.

“By adding Intrarosa™ to Mundipharma’s growing portfolio and working closely with Dr Fernand Labrie, we will be able to rapidly introduce this new therapy to healthcare providers and their patients. It will allow Mundipharma to address unmet patient needs across the continuum of women’s healthcare. It represents the continued development of its women’s health division as part of the company’s ongoing growth strategy” – he added.

“As a non-estrogen containing treatment, Intrarosa™ is a novel vaginal prescription therapy that locally replaces inside the cells what is missing for patients with vulvovaginal atrophy and moderate-to-severe dyspareunia, the most bothersome  symptom of vulvovaginal atrophy or genitourinary syndrome of menopause ” said Dr. Fernand Labrie, founder and Chief Executive Officer of Endoceutics. He also highlighted that “Intrarosa™ permits the body’s natural ability to produce hormones intracellularly and locally, thus reducing pain at sexual activity without influencing the other tissues. Since Intrarosa™ is not an estrogen, patients may feel more comfortable seeking treatment.

Dr. Fernand Labrie also added “Unlike other medications that contain estrogens, Intrarosa™ was approved by the US FDA with no black box warning. Based upon highly supporting data, Intrarosa™ is currently being studied in clinical trials performed in the US and Canada for the treatment of sexual dysfunction, an unmet medical need.”

For more information, please visit:


1 – Intrarosa US Prescribing Information

SOURCE Mundipharma

TuneGO® Closes Series B Financing Round

TuneGO® Closes Series B Financing Round

The music technology platform raised more than $7.7 million

PR Newswire

LAS VEGAS, May 18, 2018 /PRNewswire/ – TuneGO® Inc., a technology platform that connects artists with the music industry, announced today that it has successfully completed its Series B financing, totaling more than $7.7 million. Private equity firm Falcon Capital led the Series B financing round.

TuneGO will use the proceeds to advance their objective of transforming the music industry through the development of technology and application of Big Data. This successful funding round will allow TuneGO to continue on this trajectory, enhancing its technology platform and global infrastructure, which is already connected to many of the world’s leading music and entertainment companies. The company will also increase the size of its engineering team, invest in user growth and continue to expand into new international markets, particularly in Asia.

“With the explosive growth of the global music market, our investors understand the breadth and scope that TuneGO is capable of reaching, especially with the Big Data we are able to generate. Big Data, which is the new currency in the music industry, both for the independent artist and music executives, drives talent and content decisions by industry insiders and with our unique model, we are leading the way,” said John Kohl, co-founder and CEO, TuneGO.

With the recent introduction of its exclusive portal for music industry decision makers and influencers, TuneGO is living up to its mission. The portal, which aggregates a wide variety of data points that can be customized to meet an influencer’s needs, is providing record labels, music supervisors, talent agents and playlist curators a new way to streamline and simplify the discovery of talent and content while at the same time keeping track of artists and music already on their roster. The industry portal is currently in use by a select group of TuneGO partners and access to the portal is by invite only. 

“TuneGO, a next-generation music platform, will continue to innovate, connecting artists to the music industry with unprecedented access. We are always challenging the norms, and innovating products to usher in a new era in many categories, including rights management, royalty transparency for artists and how artists securely store and share their music with the world,” said Kohl. “Our distribution platform is unlike anything else offered today and will be the most artist-friendly distribution model ever offered to the marketplace.” 

“TuneGO’s platform has become a valuable tool to both music industry executives and artists. By re-thinking the way talent acquisition happens, they are undoubtedly changing the paradigm going forward,” said Wilson Rondini, managing partner Falcon Capital. “With the tremendous growth in the music industry, the timing for TuneGO is now, and this is reflected by the success of this series funding.”

TuneGO, which is free for members, is continuously monitoring its music platform for new artists with Big Data activity. Artists’ activity on the TuneGO platform is collected from multiple online and offline sources, such as social media followers, fan engagement and industry feedback. A strong ranking on TuneGO can provide artists with access to career-boosting benefits including personalized A&R services, radio airplay, sync-licensing, music reviews, access to the world’s most accomplished producers and introductions to major music labels.  

For more information about TuneGO visit, or contact TuneGO at

About TuneGO® Inc.
TuneGO® Inc. is a technology platform and interactive community that connects artists with the music industry.  TuneGO helps emerging and established artists build their fan base and grow as artists through personalized career development tools.  TuneGO provides artists with access to industry opportunities including virtual A&R services, sync licensing deals, radio airplay, connections with the world’s most accomplished music producers, introductions to music labels, and more.  TuneGO has established partnerships and relationships with many of the world’s leading music and entertainment companies. For more information, visit, or contact TuneGO at TuneGO is a free download in the app store.   


(702) 685-7450


Cision View original content:


REBBL Secures $20 Million In Funding Led By CAVU Venture Partners

REBBL Secures $20 Million In Funding Led By CAVU Venture Partners

The functional beverage brand continues exponential growth thanks to a winning trifecta of conscious capitalism, trending plant-based beverages and flat-out delicious flavors

PR Newswire

EMERYVILLE, Calif., May 18,  2018 /PRNewswire/ – REBBL, crafter of organic coconut-milk based super-herb drinks, has announced the closing of $20 million in funding led by CAVU Venture Partners, a VC and growth equity firm started by consumer products veterans known for backing and building iconic consumer brands such as BAI Brands, Health-Ade Kombucha, and Bulletproof Coffee. Since its launch in 2011, REBBL has seen triple digit growth, prompting the interest of industry leaders from key investment companies such as BIGR Ventures and PowerPlant Ventures, in addition to CAVU. Much of this growth can be attributed to the brand being on the forefront of many current trends such as plant-based and functional beverages, impact-sourcing and conscious capitalism, as well as the company’s fanatical focus on creating exceptional tasting products.

“We are so excited to welcome CAVU Venture Partners to the REBBL family,” says Sheryl O’Loughlin, CEO of REBBL. “It was important to our team that whoever we brought on during this round of funding felt as passionate as we do about our REBBL mission. CAVU exemplifies this and co-founder, Clayton Christopher, will join our board. With his experience as a founder of Sweet Leaf Tea and Deep Eddy Vodka, his addition will enhance the deep brain trust already in place. This includes the best of the best in the beverage industry such as Duane Primozich from BIGR Ventures and Mark Rampolla from PowerPlant Ventures, whose forward-thinking, companies also chose to continue to invest in the brand.”

The funding will allow REBBL to grow their team, increase marketing efforts to drive greater household penetration, expand the sales function and enhance R&D. The large round of funding also means that REBBL can continue to further their mission to create a future without human trafficking in partnership with their non-profit partner, Not For Sale, who co-founded the beverage company. REBBL is deeply purpose-driven and impact-sources its organic ingredients in 29 countries, in addition to making a 2.5 percent donation of net sales of every bottle back to Not For Sale. In a crowded marketplace, it is this mission that sets REBBL apart from the competition and attracts not only key investors, but top talent to their leadership team.

“When Not for Sale set out to create a company to further its mission, we could have never imagined what a success it would be,” says Dave Batstone, President of Not for Sale and REBBL board member. “To date, REBBL has donated over $630,000 to help our mission of creating a future without human trafficking and we know with this additional capital, the deeply experienced team at REBBL will grow this number in the years to come, giving more back to the world we live in.”

Beyond the mission, REBBL is a leader in the new, totally-natural functional beverage category where the efficacious functionality comes purely from the power of plants.  As a super herb beverage pioneer, REBBL creates exquisite-tasting, nutrient-dense drinks that are plant-based, organic, non-GMO, and free of flavor chemicals, gums, thickeners and carrageenan. Their on-trend, yet disruptive product portfolio soulfully crafts the best of the Plant Queendom to create functional organic beverages, utilizing adaptogens and super-herbs such as matcha, turmeric, ashwagandha, maca and schizandra. The results are flat-out delicious flavors that have attracted a highly engaged tribe of consumers that will only continue to expand with the company’s growth. REBBL is the top performing brand in the functional set within the natural space and their beverages can now be found nationwide in 7,000 retailers with continued expansion in 2018.  

“We’ve long admired REBBL not just for its exceptional products, but also for its mission to make a real difference in the world,” says Clayton Christopher, co-founder and Managing Partner at CAVU Venture Partners. “Their seasoned management team spearheaded by CEO Sheryl O’Loughlin and co-founder Palo Hawken know inside and out who they are as a brand. REBBL has disrupted the functional beverage space while simultaneously highlighting the positive impact an innovative social enterprise can have on our world.”

For more information about REBBL, please visit


We are REBBL. Righteous Plant Alchemy™, A Botanical Revolution for Good™. A celebration of the traditional super-herb wisdoms refined over millennia, which are only now being openly shared, studied and embraced globally. Thousands of years of collective intelligence are captured in every bottle of our super-herb, adaptogen powered Elixirs and Proteins to deliver delicious and nourishing goodness. Every bottle of REBBL is based in coconut milk, certified organic, soy and dairy free, gluten free, GMO free, and made without cane sugar, carrageenan, thickeners, gums, natural flavors or agave.

REBBL was born out of a conscious collaboration between global thought-leaders, whose soul purpose was to address the malfunctioning global food system through a regenerative business model that would respect, uplift, and delight the world. REBBL partners with Not For Sale, with a goal to create a future without human trafficking, and donates 2.5 percent of net revenue from the sale of every bottle to Not For Sale to rehabilitate survivors of trafficking. REBBL and Not for Sale also works REBBL’s growers to support their livelihood, so the grower communities are not vulnerable to trafficking.

About CAVU Venture Partners

CAVU Venture Partners invests in high growth, iconic consumer brands. CAVU was founded by consumer products veterans and serial entrepreneurs Rohan Oza, Clayton Christopher, and Brett Thomas. CAVU (Ceiling and Visibility Unlimited) is a pilot term for the best possible flying conditions. Using their deep brand-building and operational expertise, CAVU’s partners seek to create the best possible conditions to enable their talented, passionate entrepreneurs to achieve their dreams. Brands include Bai, Vital Proteins, Health-Ade, One Bar, Kite Hill, Bulletproof, WTRMLN WTR and Good Culture. For more information, please visit


Cision View original content: